Buy Lenvanix 4 mg (Lenvatinib)

Description

What is Lenvanix 4 mg (Lenvatinib)?

Lenvanix (Lenvatinib) is used to treat a certain type of thyroid cancer that has returned or that has spread to other parts of the body and cannot be treated with radioactive iodine. Lenvatinib is also used along with everolimus to treat renal cell carcinoma (RCC, a type of cancer that begins in the kidney) in people who have previously received treatment with another chemotherapy medication.

Lenvatinib is also used along with pembrolizumab as an initial treatment for advanced renal cell carcinoma. Lenvatinib is also used to treat hepatocellular carcinoma (HCC; a type of liver cancer) that cannot be treated with surgery. Lenvatinib is also used along with pembrolizumab to treat a certain type of cancer of the endometrium (lining of the uterus) that has spread to other parts of the body or worsened during or after treatment with chemotherapy medications or that cannot be treated with surgery or radiation therapy.

Lenvatinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps stop the spread of cancer cells. To know more about lenvatinib visit here.

Why should you buy the generic Lenvanix 4 mg online?

First of all generic Lenvanix is very affordable version of Lenvatinib for thyroid cancer patients.  It is a verified generic version of Lenvima. Beacon pharmaceuticals Limited manufacture this generic version in Bangladesh. It is one of the renowned pharmaceutical companies who mostly made cancer medicine in Bangladesh.

After the Directorate General of Drug Administration of Bangladesh approves to manufacture Lenvatinib, they started to make it and sell it all over the world where generic medicine is allowed to use. It is the first generic version of Lenvima which is selling regularly all over the world. It is also 95% cheaper than the brand version Which cost you less than 200 dollars. If you are looking for more cheaper lenvatinib alternative than you can also purchase Lenvaxen.

COMPOSITION

Lenvanix 4 Capsule: Each capsule contains Lenvatinib Mesylate INN equivalent to Lenvatinib 4 mg.
Lenvanix 10 Capsule: Each capsule contains Lenvatinib Mesylate INN equivalent to Lenvatinib 10 mg.

THERAPEUTIC CLASS

Anti-cancer

CLINICAL PHARMACOLOGY OF LENVANIX

Mechanism of Action

Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4; the platelet derived growth factor receptor alpha (PDGFRα), KIT, and RET.

The combination of Lenvatinib and Everolimus showed increased antiangiogenic and antitumor activity as demonstrated by decreased human endothelial cell proliferation, tube formation, and VEGF signaling in vitro and tumor volume in mouse xenograft models of human renal cell cancer greater than each drug alone.

Pharmacodynamics

Cardiac Electrophysiology: A single 32 mg dose (1.3 times the recommended daily dose) of Lenvatinib did not prolong the QT/QTc interval in a thorough QT study in healthy subjects. However, QT prolongation was observed in clinical studies.

Pharmacokinetics

Absorption: After oral administration of Lenvatinib, time to peak plasma concentration (Tmax) typically occurred from 1 to 4 hours post-dose. Administration with food did not affect the extent of absorption, but decreased the rate of absorption and delayed the median Tmax from 2 hours to 4 hours.

In patients with solid tumors administered single and multiple doses of Lenvanix once daily, the maximum Lenvatinib plasma concentration (Cmax) and the area under the concentration-time curve (AUC) increased proportionally over the dose range of 3.2 to 32 mg with a median accumulation index of 0.96 (20 mg) to 1.54 (6.4 mg).

Distribution: In vitro binding of Lenvatinib to human plasma proteins ranged from 98% to 99% (0.3 – 30 µg/mL). In vitro, the Lenvatinib blood-to-plasma concentration ratio ranged from 0.589 to 0.608 (0.1 – 10 µg/mL). Based on in vitro data, Lenvatinib is a substrate of P-gp and BCRP but not a substrate for organic anion transporter (OAT)1, OAT3, organic anion transporting polypeptide (OATP) 1B1, OATP1B3, organic cation transporter (OCT)1, OCT2, or the bile salt export pump (BSEP).

Metabolism: CYP3A is one of the main metabolic enzymes of Lenvatinib. The main metabolic pathways for Lenvatinib in humans were identified as enzymatic (CYP3A and aldehyde oxidase) and non-enzymatic processes.

Excretion: Ten days after a single administration of radiolabeled Lenvatinib to 6 patients with solid tumors, approximately 64% and 25% of the radiolabel were eliminated in the feces and urine, respectively.

Elimination: Plasma concentrations declined bi-exponentially following Cmax. The terminal elimination half-life of Lenvatinib was approximately 28 hours.

INDICATIONS

Lenvatinib is a kinase inhibitor that is indicated for:

Hepatocellular Carcinoma (HCC): As first line therapy in patients with unresectable hepatocellular carcinoma.

Differentiated Thyroid Cancer (DTC): Single agent for patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory DTC.

Renal Cell Cancer (RCC): Use in combination with Everolimus, for patients with advanced RCC following one prior anti-angiogenic therapy.

DOSAGE AND ADMINISTRATION

Recommended dose (HCC): 12 mg orally, once daily (for adults weighing >_60 Kg). 8 mg orally, once daily for adults weighing <60 Kg).

Recommended dose (DTC): 24 mg orally, once daily.

Recommended dose (RCC): 18 mg Lenvatinib + 5 mg Everolimus, orally, once daily

Administration Instructions: Lenvatinib capsules should be swallowed whole. Alternatively, the capsules can be dissolved in a small glass of liquid. Measure 1 tablespoon of water or apple juice and put the capsules into the liquid without breaking or crushing them. Leave the capsules in the liquid for at least 10 minutes. Stir for at least 3 minutes. Drink the mixture. After drinking, add the same amount (1 tablespoon) of water or apple juice to the glass. Swirl the contents a few times and swallow the additional liquid.

USE IN SPECIFIC POPULATIONS

Pregnancy

Lenvatinib can cause fetal harm when administered to pregnant woman.

Lactation

Risk Summary: It is not known whether Lenvatinib is present in human milk. However, Lenvatinib and its metabolites are excreted in rat milk at concentrations higher than in maternal. Because of the potential for serious adverse reactions in nursing infants from Lenvatinib, advise women to discontinue breastfeeding during treatment with Lenvatinib.

Females and Males of Reproductive Potential

Contraception

Based on its mechanism of action, Lenvatinib can cause fetal harm when administered to a pregnant woman. Advise females of reproductive potential to use effective contraception during treatment with Lenvatinib and for at least 2 weeks following completion of therapy.

Infertility

Females: Lenvatinib may result in reduced fertility in females of reproductive potential.
Males: Lenvatinib may result in damage to male reproductive tissues leading to reduced fertility of unknown duration.

Pediatric Use

The safety and effectiveness of Lenvatinib in pediatric patients have not been established

Geriatric Use

Conclusions are limited due to the small sample size, but there appeared to be no overall differences in safety or effectiveness between subjects and younger subjects.

Renal Impairment

No dose adjustment is recommended in patients with mild or moderate renal impairment. In patients with severe renal impairment, the recommended dose is 14 mg in the treatment of DTC and 10 mg in the treatment of RCC, either taken orally once daily. Patients with end stage renal disease were not studied.

Hepatic Impairment

No dose adjustment is recommended in patients with mild or moderate hepatic impairment. In patients with severe hepatic impairment, the recommended dose is 14 mg in the treatment of DTC and 10 mg in the treatment of RCC, either taken orally once daily.

OVERDOSAGE

There is no specific antidote for overdose with Lenvatinib. Due to the high plasma protein binding, Lenvatinib is not expected to be dialyzable. Adverse reactions in patients receiving single doses of Lenvatinib as high as 40 mg were similar to the adverse events reported in the clinical studies at the recommended dose for DTC and RCC.

CONTRAINDICATIONS

None.

WARNINGS AND PRECAUTIONS

Hypertension
Control blood pressure prior to treatment with Lenvatinib. Withhold Lenvatinib for Grade 3 hypertension despite optimal antihypertensive therapy. Discontinue for life-threatening hypertension.

Cardiac Failure
Monitor for clinical symptoms or signs of cardiac decompensation. Withhold Lenvatinib for Grade 3 cardiac dysfunction. Discontinue for Grade 4 cardiac dysfunction.

Arterial Thromboembolic Events
Discontinue Lenvatinib following an arterial thromboembolic event.

Hepatotoxicity
Monitor liver function tests before initiation of Lenvatinib and periodically throughout treatment. Withhold Lenvatinib for Grade 3 or greater liver impairment. Discontinue for hepatic failure.

Proteinuria
Monitor for proteinuria before initiation of, and periodically throughout, treatment with Lenvatinib. Withhold Lenvatinib for 2 grams of proteinuria for 24 hours. Discontinue for nephrotic syndrome.

Diarrhea
May be severe and recurrent. Use standard anti-diarrheal therapy. Withhold Lenvatinib for Grade 3 and discontinue for Grade 4 diarrhea.

Renal Failure and Impairment
Withhold Lenvatinib for Grade 3 or 4 renal failure/impairment.

Gastrointestinal Perforation and Fistula Formation
Discontinue Lenvatinib in patients who develop gastrointestinal perforation or life threatening fistula.

QT Interval Prolongation
Monitor and correct electrolyte abnormalities in all patients. Withhold Lenvatinib for the development of Grade 3 or greater QT interval prolongation.

Hypocalcemia
Monitor blood calcium levels at least monthly and replace calcium as necessary.

Reversible Posterior Leukoencephalopathy Syndrome (RPLS)
Withhold Lenvatinib for RPLS until fully resolved.

Hemorrhagic Events
Withhold Lenvatinib for Grade 3 hemorrhage. Discontinue for Grade 4 hemorrhage. Impairment of Thyroid Stimulating Hormone Suppression/Thyroid Dysfunction Monitor TSH levels monthly and use thyroid replacement medication as needed.

Embryofetal Toxicity
Can cause fetal harm. Advise of potential risk to a fetus and use of effective contraception.

ADVERSE REACTIONS

In DTC, the most common adverse reactions (incidence greater than or equalto 30%) for Lenvatinib are hypertension, fatigue, diarrhea, arthralgia/myalgia, decreased appetite, weight decreased, nausea, stomatitis, headache, vomiting, proteinuria, palmar-plantar erythrodysesthesia syndrome, abdominal pain, and dysphonia.

In RCC, the most common adverse reactions (greater than 30%) for Lenvatinib + Everolimus are diarrhea, fatigue, arthralgia/myalgia, decreased appetite, vomiting, nausea, stomatitis/oral inflammation, hypertension, peripheral edema, cough, abdominal pain, dyspnea, rash, weight decreased, hemorrhagic events, and proteinuria.

DRUG INTERACTIONS

Effect of Other Drugs on Lenvatinib
No dose adjustment of Lenvatinib is recommended when co-administered with CYP3A, P-glycoprotein (P-gp), and breast cancer resistance protein (BCRP) inhibitors and CYP3A and P-gp inducers.

PHARMACEUTICAL INFORMATION

Storage Conditions
Store in a cool and dry place, away from light. Keep out of the reach of children.

Presentation & Packaging
Lenvanix 4 Capsule: Each commercial box contain 30 capsules in a Pot.
Lenvanix 10 Capsule: Each commercial box contain 30 capsules in a Pot.

Buy Lenvanix 4 Mg Online

Are you interested to buy Lenvanix 4 mg online? or you need 10 mg version? Don’t worry. 100 Meds can help you to find reliable and verified medicine at affordable cost. Please contact our support team by using email, whatsapp or wechat. Even you can contact our facebook page.